AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14977479
Drug: High-dose immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose immunosuppression followed by autologous hematopoietic stem cell transplantation
Trial: 14977479
Drug: Mitoxantrone (best
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (best available therapy)
Trial: 11566828
Drug: Voice therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice therapy for six weeks
Trial: 3063046
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: Anesthesia induced with diazepam (94 micrograms x kg‐1), thiopentone (3 mg x kg‐1), and fentanyl (3 micrograms x kg‐1)
Trial: 12657406
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (normal saline)
Trial: 29122812
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (100 mg/d)
Trial: 23388543
Drug: Azathioprine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 2.0 to 2.5 mg/kg per day
Trial: 23388543
Drug: Mesalamine 4
RxNorm normalized name: mesalamine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 4 g/d
Trial: 19083482
Drug: L-ornithine (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine (2000 mg/d for 7 days and 6000 mg/d for 1 day as L-ornithine hydrochloride)
Trial: 19083482
Drug: L-ornithine
RxNorm normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine
Trial: 12180579
Drug: Erythromycin 200
RxNorm normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 200 mg
Trial: 3987183
Drug: Morphine 8
RxNorm normalized name: morphine 8 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 8 mg
Trial: 11144396
Drug: Cefdinir 14
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 14 mg/kg/day divided twice a day for 5 days
Trial: 11144396
Drug: Cefprozil 30
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefprozil 30 mg/kg/day divided twice a day for 10 days
Trial: 30096092
Drug: Rifaximin (1100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (1100 mg/day)
Trial: 9416884
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 to 40 mg daily
Trial: 15278040
Drug: Mechanical methods
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical methods of hemostasis plus epinephrine injection
Trial: 15278040
Drug: Epinephrine injection
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine injection alone
Trial: 11804427
Drug: Nafarelin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin (200 microg by nasal route twice a day)
Trial: 11804427
Drug: Leuprolide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide (0.5 mg by subcutaneous route once a day)
Trial: 8203940
Drug: Movement therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movement therapy
Trial: 28543914
Drug: Intervention premises
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention premises audited by Environmental Health Practitioners with varying doses (informal advice, written advice, follow-up visits)
Trial: 18245177
Drug: D-cycloserine, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine, 100 mg
Trial: 27725657
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI) treatment
Trial: 15231442
Drug: Successful treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful treatment with antidepressants
Trial: 22932947
Drug: Soft gel
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gel capsule L-T4 taken with water (proper habit, PH)
Trial: 22932947
Drug: Soft gel
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gel capsule L-T4 taken with coffee ≤ 5 min later (improper habit, IH)
Trial: 22932947
Drug: Soft gel
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gel capsule L-T4 taken with water (PH)
Trial: 22932947
Drug: Soft gel
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gel capsule L-T4 taken with coffee (IH)
Trial: 20798662
Drug: 30 min
RxNorm normalized name: Goddess Garden SPF 30 Mineral Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 min of daily walking at 60% VO(2max) for 1 week in sedentary men (Study 2)
Trial: 8501502
Drug: Cyclophosphamide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 600 mg/m2 + Carboplatin 300 mg/m2
Trial: 8501502
Drug: Single-agent Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-agent Carboplatin
Trial: 3114783
Drug: Caffeine 32
RxNorm normalized name: caffeine 32 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 32 mg
Trial: 3114783
Drug: Caffeine 64
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 64 mg
Trial: 3114783
Drug: Caffeine 128
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 128 mg
Trial: 3114783
Drug: Caffeine 256
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 256 mg
Trial: 19764439
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl analgesia
Trial: 21543429
Drug: EST expression
RxNorm normalized name: SODIUM FLUORIDE 243 mg in 1 g ORAL PASTE, DENTIFRICE [Crest Expressions Scope]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EST expression in subcutaneous adipose tissue
Trial: 20415678
Drug: Microsphere adapalene
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microsphere adapalene gel, applied once daily in the evening for 12 weeks
Trial: 20415678
Drug: Conventional adapalene
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional adapalene gel, applied once daily in the evening for 12 weeks
Trial: 20415678
Drug: Microsphere adapalene
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microsphere adapalene gel
Trial: 20415678
Drug: Conventional adapalene
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional adapalene gel
Trial: 15155217
Drug: Single-dose voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose voriconazole (3 mg/kg)
Trial: 15155217
Drug: Single-dose voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose voriconazole (4 mg/kg)
Trial: 15155217
Drug: Multiple-dose voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose voriconazole (6 mg/kg every 12 h on day 1, followed by 3 mg/kg every 12 h on day 2 to day 4 and 4 mg/kg every 12 h on day 4 to day 8)
Trial: 15155217
Drug: Voriconazole (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (any dosage)
Trial: 15155217
Drug: Voriconazole (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (4 mg/kg)
Trial: 1146748
Drug: 34 g
RxNorm normalized name: Droplet Micron Pen Needles 34 g X 3.5 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 34 g protein intake
Trial: 1146748
Drug: 57 g
RxNorm normalized name: HYDROGEN PEROXIDE 8.57 g in 100 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 57 g protein intake
Trial: 1146748
Drug: 88 g
RxNorm normalized name: Sutab, 0.225 g-0.188 g-1.479 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 88 g protein intake
Trial: 27305512
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no gel applied)
Trial: 24766062
Drug: Primary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary care treatment
Trial: 19880461
Drug: Specialty care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialty care treatment
Trial: 17005105
Drug: Medication (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (both pramipexole and amantadine)
Trial: 9077538
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (Ca-suppl.) with 850 mg of calcium daily for 1 year
Trial: 30047245
Drug: 60‐mg iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60‐mg iron and folic acid (IFA)
Trial: 30047245
Drug: 20‐mg iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20‐mg iron plus 17 micronutrients in a capsule (MMN)
Trial: 30047245
Drug: lipid‐based nutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipid‐based nutrient supplement (LNS; 118 kcal) with 20‐mg iron plus 21 micronutrients, protein, and fat
Trial: 21449784
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (boceprevir plus peginterferon-ribavirin) for patients with undetectable HCV RNA at week 8
Trial: 21449784
Drug: Erythropoietin administration
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin administration in boceprevir-treated patients
Trial: 16056097
Drug: 0.2 g
RxNorm normalized name: methionine 0.2 gram ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g acidic oligosaccharides
Trial: 16056097
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.2 g acidic oligosaccharides and 0.6 g neutral oligosaccharides
Trial: 12413624
Drug: 0.75‐mg levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75‐mg levonorgestrel 12 h apart (group A)
Trial: 12413624
Drug: 1.5‐mg levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5‐mg levonorgestrel (group B)
Trial: 7652667
Drug: Radiochemotherapy (2‐course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiochemotherapy (2‐course radiation treatment of 60 to 70 Gy total dose in combination with mitomycin C and 5‐fluorouracil)
Trial: 2503723
Drug: buserelin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buserelin (500 micrograms daily subcutaneously) and nilutamide (300 mg daily by mouth)
Trial: 412610
Drug: 2% aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% aqueous solution of sodium cromoglycate delivered by a metered dose nasal spray
Trial: 23909699
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg intranasal SB‐705498
Trial: 8797769
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2, 3-hour infusion
Trial: 8797769
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2, 6-hour infusion
Trial: 8797769
Drug: Paclitaxel 135
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 135 mg/m2, 3-hour infusion
Trial: 8797769
Drug: Paclitaxel, 24-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel, 24-hour infusion
Trial: 1739926
Drug: High-dose megestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose megestrol acetate for 1 month
Trial: 1739926
Drug: High-dose megestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose megestrol acetate after crossover from placebo
Trial: 27257049
Drug: Sequential Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Therapy (ST)
Trial: 29146042
Drug: Online computerized
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online computerized cognitive behavioral therapy (MoodGYM) in addition to usual treatment
Trial: 19772969
Drug: Metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin therapy (425 mg/d for 2 years, then 850 mg/d for 2 years)
Trial: 17824901
Drug: Pregabalin, 225
RxNorm normalized name: Pregabalin, 225 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin, 225 mg per day
Trial: 2406852
Drug: Oral bismuth
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bismuth subsalicylate (600 mg three times daily)
Trial: 1418071
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg/d)
Trial: 2406852
Drug: Oral bismuth
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bismuth subsalicylate
Trial: 2548222
Drug: Clonidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.2 mg)
Trial: 16733374
Drug: IFN-alpha induction
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha induction (6 MU daily for 2 weeks, then 3 MU daily for 2 weeks, then 3 MU tiw for 20 weeks)
Trial: 16733374
Drug: Ribavirin (1-1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (1-1.2 g daily for 24 weeks)
Trial: 9924265
Drug: 20 mmol/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mmol/d Ca supplement (about 40 mmol Ca/d)
Trial: 7827299
Drug: Trimethadione (0.9-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethadione (0.9-1.5 g daily)
Trial: 7827299
Drug: Trimethadione treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethadione treatment
Trial: 31539060
Drug: CS200 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS200 (200 mg chitosan per kg feed)
Trial: 31539060
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg chitosan per kg feed)
Trial: 30579508
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (details not specified)
Trial: 26099138
Drug: Clonidine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (3 µg/kg loading then 0-3 µg/kg/hour)
Trial: 26099138
Drug: Midazolam (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (200 µg/kg loading then 0-200 µg/kg/hour)
Trial: 22843943
Drug: Dose-dense sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense sequential chemotherapy (DD-CT) with epirubicin followed by paclitaxel every 2 weeks
Trial: 22843943
Drug: Conventionally-dosed chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally-dosed chemotherapy (CD-CT) with epirubicin and paclitaxel simultaneously every 3 weeks
Trial: 22843943
Drug: Breast-conserving surgery
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-conserving surgery after neoadjuvant chemotherapy
Trial: 22843943
Drug: Mastectomy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mastectomy after neoadjuvant chemotherapy
Trial: 19824805
Drug: Propofol 1
RxNorm normalized name: propofol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1 mg.kg(‐1) (group II)
Trial: 19824805
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg.kg(‐1) (group III)
Trial: 19824805
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg.kg(‐1) (group IV)
Trial: 16436011
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and lifestyle intervention including monthly lecture-discussion sessions for 10 months, small group counseling, and educational materials based on WCRF Diet and Health Recommendations for Cancer Prevention.
Trial: 10741150
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose therapy with HSCT
Trial: 28844307
Drug: Delayed induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed induction protocol (calcium hydroxide as intracanal medication following AAE guidelines)
Trial: 21715522
Drug: Jet injection
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet injection of insulin aspart (0.2 units/kg body wt)
Trial: 21715522
Drug: Conventional pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pen injection of insulin aspart (0.2 units/kg body wt)
Trial: 15454021
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine gluconate mouthrinse with oral hygiene instruction (OHI)
Trial: 15454021
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline mouthrinse with no oral hygiene instruction (OHI)
Trial: 15454021
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline mouthrinse with oral hygiene instruction (OHI)
Trial: 10332346
Drug: Mouthrinse intervention;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthrinse intervention; details on dosage and duration not available.
Trial: 8388007
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (1%) administered four times daily
Trial: 27432604
Drug: Surotomycin 250
RxNorm normalized name: Surotomycin
DrugBank: Surotomycin (DB12076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surotomycin 250 mg twice daily
Trial: 27432604
Drug: Vancomycin 125
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 125 mg four times daily
Trial: 27432604
Drug: Surotomycin 125
RxNorm normalized name: Surotomycin
DrugBank: Surotomycin (DB12076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surotomycin 125 mg twice daily
Trial: 16572429
Drug: Remission induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remission induction chemotherapy
Trial: 10871578
Drug: Standard parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parenteral nutrition (PN) containing conventional amounts of dextrose, amino acids, micronutrients, and lipid (120 kJ/d)
Trial: 10871578
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition containing only micronutrients and a small amount of lipid (12 kJ/d)
Trial: 9408513
Drug: Oral angiotensin-converting-enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral angiotensin-converting-enzyme (ACE) inhibitors
Trial: 8257180
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (r‐HuEpo) administered subcutaneously twice a week
Trial: 27075705
Drug: CDP/BPO (clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP/BPO (clindamycin 1%/benzoyl peroxide 5%) once daily gel
Trial: 27075705
Drug: CDP (clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP (clindamycin 1%) twice daily gel
Trial: 25566615
Drug: Kuntai Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuntai Capsule (KC) combined with gonadotropin-releasing hormone agonist (GnRH-a)
Trial: 25566615
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a) alone
Trial: 24393456
Drug: Varenicline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (2 mg)
Trial: 9840564
Drug: Single-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intramuscular methotrexate (1 mg/kg)
Trial: 28671626
Drug: Hypoxia +
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxia + Carbohydrate (200 mL/20 min maltodextrin)
Trial: 28671626
Drug: Hypoxia +
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxia + Glutamine (20 g/day) and 8% maltodextrin (200 mL/20 min)
Trial: 24491065
Drug: Physical fitness
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical fitness training (supported or unsupported treadmill training; cardiovascular active aerobic training; five times per week, over 4 weeks; each session 50 minutes; total of 20 sessions) in addition to standard rehabilitation treatment